All Systems Go For Novartis 'World-First' Leqvio Pact With England

Some 20 months after unveiling a landmark alliance with NHS England to give at-risk patients speedy access to Leqvio, Novartis AG has now secured reimbursement in the country for the gene silencing cholesterol lower which could be used to treat hundreds of thousands of cardiovascular patients over the next three years.

The wide-ranging "world-first" collaboration, initially trumpeted at the J.P. Morgan Healthcare Conference in January 2020 and almost a year before...